The efficiency and safety of trastuzumab and lapatinib added to neoadjuvant chemotherapy in Her2-positive breast cancer patients: a randomized meta-analysis

BACKGROUND: The addition of human epidermal growth factor receptor 2 (Her2) therapies to neoadjuvant chemotherapy (NAC) during treatment of Her2-positive breast cancer has been proposed as an effective way to improve the prognosis. However, the treatment outcomes of adding trastuzumab, lapatinib, or...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Zhe-Ling, Shen, Yan-Wei, Li, Shu-Ting, Li, Chun-Li, Zhang, Ling-Xiao, Yang, Jiao, Lv, Meng, Lin, Ya-Yun, Wang, Xin, Yang, Jin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2016
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4892834/
https://www.ncbi.nlm.nih.gov/pubmed/27313469
http://dx.doi.org/10.2147/OTT.S106055

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4892834/
https://www.ncbi.nlm.nih.gov/pubmed/27313469
http://dx.doi.org/10.2147/OTT.S106055

Ejemplares similares